What Is Sativex and Who Can Get It in the UK?

In recent years, there has been growing interest in cannabis-based medicines, especially products like Sativex THC CBD spray. Patients and healthcare professionals alike are seeking clarity about what these medicines are, who can access them, and the legal framework surrounding them. This post unpacks these questions and navigates the often-confused landscape of cannabis regulation in the UK.

What Is Sativex?

Sativex is a cannabis-based prescription medicine that combines two key active ingredients from the cannabis plant: tetrahydrocannabinol (THC) and cannabidiol (CBD). Delivered as an oral spray, it is licensed in the UK specifically for patients with spasticity due to multiple sclerosis (MS) that has not responded adequately to other treatments.

The spray works by targeting nerve signals that cause muscle stiffness and spasms, helping to reduce symptoms that can severely impact mobility and quality of life.

Licensed Status and Manufacture

Sativex is classed as a licensed medicinal product in the UK, meaning it has undergone clinical trials and regulatory approval processes to ensure safety and efficacy. It is manufactured by GW Pharmaceuticals, a UK company, and distributed through authorised pharmacies, including specialist suppliers like Nationwide Pharmacies.

This sets it apart from other cannabis products that might be sold illegally or as unregulated supplements.

Class vs Schedule: Clarifying Common Confusions

One source of persistent confusion is the misuse or conflation of the terms "Class" and "Schedule" in relation to controlled drugs in the UK.

Class is a categorisation used under the Misuse of Drugs Act 1971 to indicate the level of harm and penalties associated with a substance. Classes range from A (most serious) to C (least serious).
Schedule is a different classification under the Misuse of Drugs Regulations 2001 describing the licensing, supply, and possession controls on medicines containing controlled substances.

For example, cannabis is a Class B drug under the 1971 Act, signalling it is an illegal controlled substance with significant penalties for unauthorised possession or supply.

However, medicinal forms of cannabis like Sativex are typically placed in Schedule 4 or Schedule 2 under the 2001 Regulations, depending on formulation, which sets the rules for their legal prescription, storage, and dispensing.

Understanding this distinction is crucial when discussing why cannabis remains illegal generally, but licensed medicines containing cannabinoids can be prescribed legally in the UK.

What Changed in November 2018?

November 2018 marked a significant milestone in UK cannabis law. The Home Office reclassified cannabis-derived medicinal products (CDMPs), paving the way for specialist doctors to prescribe them legally on the NHS or privately.

Prior to this, medicinal cannabis products were essentially illegal, except in a handful of cases or through complex import permissions.

This change meant:

Specialist prescribing: Only doctors on the General Medical Council's specialist register can prescribe CDMPs, including Sativex, Epidyolex (for epilepsy), and unlicensed cannabis products in exceptional circumstances.
Legal clarity: Cannabis medicines no longer fell under the same restrictions as recreational cannabis under the Misuse of Drugs Act.
Supply frameworks: Pharmacies authorised to dispense these medicines emerged, including Nationwide Pharmacies, dedicated to providing licensed cannabis medicines safely and legally.

However, it is key to note that the move did not legalise recreational cannabis or broadly decriminalise possession, which remain offences under the Misuse of Drugs Act 1971.

Why Does Cannabis Remain Illegal Under the 1971 Act?

The Misuse of Drugs Act 1971 remains the cornerstone of drug control in the UK. Despite the 2018 reforms for medicinal cannabis, the Act classifies cannabis and its preparations as Class B drugs strictly controlled for non-medical use.

This means:

Possession, supply, or production of cannabis without authorisation is a criminal offence.
The Act does not distinguish between recreational cannabis and unlicensed medicinal cannabis products.
The legislation is deliberately cautious, reflecting ongoing concerns about recreational cannabis's potential harms.

So, while medicines like Sativex are exceptions authorised under separate regulations, the blanket illegality of other cannabis forms remains firmly in place.

Specialist-Only Prescribing: Why Access to Sativex Is Limited

Access to Sativex in the UK is tightly restricted due to several factors:

Specialist prescribing requirement: Only neurologists or other relevant specialists registered with the General Medical Council may initiate Sativex prescriptions. General practitioners (GPs) do not have authority to prescribe it initially.
Clinical guidelines: NHS England provides specific criteria and guidance for Sativex use, mostly limited to MS patients with moderate to severe spasticity not responsive to other treatments.
Cost considerations: Sativex is expensive, and NHS commissioning bodies apply strict cost-effectiveness evaluations before routinely funding it.
Monitoring requirements: Due to THC, patients require close monitoring for side effects and efficacy.

Consequently, NHS access can be https://dlf-ne.org/is-cannabis-legal-in-the-uk-or-not-in-2026-clearing-up-the-confusion/ limited, and many patients turn to private clinics or pharmacies, such as Nationwide Pharmacies, to obtain licensed cannabis medicines.

The Pathway to Receiving Sativex

Specialist assessment: Patient referred to a neurologist or MS specialist.
Evaluation of treatment options: Other antispasticity treatments must have been tried first.
Prescription initiation: Specialist prescribes Sativex, with follow-up plans.
Dispensing through licensed pharmacy: Including Nationwide Pharmacies which specialise in cannabis medicines.
Ongoing review: To determine treatment effectiveness and side effects.

Who Can Get Sativex in the UK?

Patient Group Eligible Conditions Prescribing Practitioner Access Route Multiple Sclerosis Patients Spasticity unresponsive to other therapies Registered Specialist (Neurologist, MS Specialist) NHS (limited) or private prescription, dispensed by licensed pharmacies (e.g., Nationwide Pharmacies) Other patients (rare, exceptional cases) Conditions considered on case-by-case basis Specialist doctor with GMC registration Private prescription

Note: GPs currently cannot initiate Sativex prescriptions but can https://bizzmarkblog.com/is-cannabis-decriminalised-anywhere-in-the-uk/ continue prescribing under specialist guidance once initiated.

Why Choose a Specialist Pharmacy Like Nationwide Pharmacies?

Specialist pharmacies such as Nationwide Pharmacies play a vital role in the delivery of licensed cannabis medicines. Their expertise includes:

Handling and storing controlled medicines under strict regulations.
Providing guidance to patients and healthcare professionals on safe, effective use.
Supporting confidential consultations and timely dispensing.
Compliance with legal and clinical governance standards.

Patients receiving Sativex can benefit from their support to ensure adherence and optimise treatment outcomes.

Takeaways

Sativex THC CBD spray is the UK’s licensed cannabis medicine for some MS patients, available by specialist prescribing only.
The distinction between cannabis being a controlled Class B drug and Sativex being a licensed medicine in Schedule 4 or 2 is key to understanding regulation.
November 2018 reforms opened legal access to cannabis medicines via specialist doctors but did not legalise recreational cannabis.
NHS access to Sativex remains limited and tightly controlled, with many patients obtaining it privately through pharmacies like Nationwide Pharmacies.
Cannabis remains illegal for general use under the 1971 Misuse of Drugs Act, reinforcing why specialist prescribing and licensed supply routes are vital.

More clarity, responsible prescribing, and informed patients will continue to shape the evolving landscape of UK licensed cannabis medicines.